<DOC>
	<DOCNO>NCT02014636</DOCNO>
	<brief_summary>This open-label , 2 part study pazopanib and/or MK 3475 treatment na√Øve subject advance RCC . Part 1 consist Phase I dose escalation pazopanib + MK 3475 follow expansion cohort determine maximum tolerate regimen recommend Phase II dose . Part 2 randomized 3-arm Phase II study evaluate clinical efficacy safety pazopanib + MK 3475 compare single-agent pazopanib single-agent MK 3475 . The objective Phase I/II study test safety tolerability pazopanib combination MK 3475 , study clinical efficacy pazopanib combination MK 3475 subject advance RCC compare single-agent pazopanib single-agent MK 3475 . Following Urgent Safety Measure ( USM ) release February 09 , 2017 , phase II ( Part 2 ) portion study commence .</brief_summary>
	<brief_title>Safety Efficacy Study Pazopanib MK 3475 Advanced Renal Cell Carcinoma ( RCC ; KEYNOTE-018 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Signed write informed consent performance studyspecific procedures assessment must willing comply treatment follow Diagnosis locally advance metastatic RCC predominantly clear cell histology Must measurable disease Subject receive prior systemic therapy A woman eligible participate study Nonchildbearing potential , negative serum pregnancy test within 7 day first dose study treatment , lactating , agree use adequate contraception study least 120 day last dose investigational product Eastern Cooperative Oncology Group performance status 0 1 Adequate organ function define protocol Left ventricular ejection fraction &gt; = low limit normal assessed echocardiogram multigated acquisition scan In France , subject eligible inclusion study either affiliate beneficiary social security category Subject active autoimmune disease document history autoimmune disease syndrome require systemic steroid immunosuppressive agent Subject currently participate participate study investigational agent use investigational device within 30 day first dose study treatment Subject expect require form systemic localize antineoplastic therapy study Subject systemic steroid therapy , within one week plan date first dose study treatment . Subject form immunosuppressive medication Subject history malignancy ( disease treatment study ) within 5 year first study treatment administration Central nervous system metastasis Unable swallow retain orally administer medication Subject interstitial lung disease history pneumonitis Active peptic ulcer disease , inflammatory bowel disease , ulcerative colitis , Gastrointestinal condition increase risk perforation ; history abdominal fistula , GI perforation , intraabdominal abscess within 4 week begin study treatment Known history HIV infection know history positive Hepatitis B Hepatitis C Presence active infection require systemic therapy Corrected QT interval duration prolongation History one follow cardiac condition within past 6 month : Cardiac angioplasty stenting ; Myocardial infarction ; Unstable angina ; History Class III IV congestive heart failure accord New York Heart Association classification History cerebrovascular accident within past 6 month Poorly control hypertension History untreated deep venous thrombosis Presence nonhealing wound , fracture , ulcer , presence symptomatic peripheral vascular disease Evidence bleed diathesis coagulopathy Recent hemoptysis Known endobronchial lesion and/or lesion infiltrate major pulmonary vessel increase risk pulmonary hemorrhage Any serious and/or unstable preexist medical , psychiatric , condition could interfere subject 's safety , obtain informed consent compliance study procedures Previous severe hypersensitivity reaction another Monoclonal antibody . Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically related excipients pazopanib tablet Has take prohibit medication list protocol within 14 day first dose study treatment . Subject receive receive live vaccine within 30 day first administration study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Pazopanib ( GW786034 )</keyword>
	<keyword>MK 3475</keyword>
	<keyword>Renal cell carcinoma</keyword>
</DOC>